Multiple Myeloma

>

Latest News

Quarterly MRD Monitoring After Daratumumab Allows Relapse Detection in Multiple Myeloma
Quarterly MRD Monitoring After Daratumumab Allows Relapse Detection in Multiple Myeloma

June 14th 2025

Results of the PREDATOR-MRD trial found that daratumumab could help predict MRD response for patients with multiple myeloma.

The median overall survival with cilta-cel exceeds 5 years among patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 trial.
Cilta-Cel Demonstrates "Curative Potential" in R/R Multiple Myeloma

June 9th 2025

The 1-year progression-free survival rate for patients in the BCMA/GPRC5D naïve RP2D group was 95.0% and across all dose levels it was 74.1%.
JNJ-79635322 Shows Safety/Favorable Responses in R/R Multiple Myeloma

June 6th 2025

MagnetisMM-6 Data Suggest Safety, Manageability of Elranatamab Combo in NDMM
MagnetisMM-6 Data Suggest Safety, Manageability of Elranatamab Combo in NDMM

June 3rd 2025

Daratumumab Plus KRd May Be a New SOC Option in NDMM
Daratumumab Plus KRd May Be a New SOC Option in NDMM

June 3rd 2025